Many cancers have defective p53 and IL24 tumor suppressor genes. These abnormalities are associated with tumor progression, treatment resistance and cancer immune suppression.

MultiVir’s investigational immune gene therapies deliver normal p53 and IL24 tumor suppressor genes into tumors to restore their function and to stimulate anti-tumor immune responses.

MultiVir utilizes genetically engineered viruses to transfer normal tumor suppressor genes into tumors. Normal tumor suppressor genes are known to activate immune responses and to inhibit immune suppressive cancer genes